Lacosamide Ascend (Lacosamide)

Lacosamide is an antiepileptic drug that modulates neuronal excitability in seizure disorders.

• Partial‑onset seizures: reduces the frequency and severity of focal seizures.
• Epilepsy (generalized): contributes to overall seizure control when used as part of a therapeutic regimen.
• Refractory epilepsy adjunct: added when other antiepileptic drugs have not achieved adequate control.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes hyper‑excitable neuronal membranes and diminishes repetitive neuronal firing. By selectively targeting the slow inactivation phase, it reduces the propagation of epileptiform activity without markedly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild to moderate stomach upset.
• Headache: tension‑type or throbbing pain.
• Fatigue: increased tiredness or lack of energy.
• Blurred vision: temporary visual disturbances.
• Diplopia: double vision, especially at higher doses.

Serious or Rare Side Effects

• Suicidal thoughts: emergence of depressive ideation.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac arrhythmia: PR‑interval prolongation or other rhythm disturbances.
• Respiratory depression: reduced breathing effort in vulnerable patients.
• Hepatic failure: signs of liver dysfunction.
• Blood dyscrasias: agranulocytosis or aplastic anemia.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

• Renal impairment: evaluate kidney function and consider dose adjustment.
• Hepatic disease: monitor liver enzymes and adjust therapy if needed.
• Cardiac conduction disorders: obtain baseline ECG and watch for PR‑interval changes.
• Concomitant CNS depressants: observe for enhanced sedation or respiratory effects.
• Pregnancy and lactation: weigh potential benefits against unknown risks; discuss with a specialist.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels.
• Other sodium‑channel blockers (e.g., lamotrigine, topiramate): increase risk of CNS depression.
• QT‑prolonging agents (e.g., erythromycin, quinidine): may exacerbate cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely)

• Alcohol: can intensify dizziness and sedation.
• Additional antiepileptics: monitor seizure control and side‑effect profile.
• SSRIs or SNRIs: watch for additive central nervous system effects.
• Antihypertensives: possible additive hypotensive effect.
• Anticoagulants: monitor for altered bleeding risk.